---
title: "為什麼 Ionis 製藥的股票在第二季度報告發布後上漲"
description: "Ionis 發佈了第二季度每股收益為 85 美分，而預期為 52 美分的虧損，收入為 4.52 億美元，超出市場共識的 2.8295 億美元。2025 財年的收入指引上調至 8.25 億至 8.5 億美元；Tryngolza 的銷售前景上調至 7500 萬至 8000 萬美元。錯過了反彈？瞭解下一批領導者將從何而來"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/250850112.md"
published_at: "2025-07-30T19:32:46.000Z"
---

# 為什麼 Ionis 製藥的股票在第二季度報告發布後上漲

> Ionis 發佈了第二季度每股收益為 85 美分，而預期為 52 美分的虧損，收入為 4.52 億美元，超出市場共識的 2.8295 億美元。2025 財年的收入指引上調至 8.25 億至 8.5 億美元；Tryngolza 的銷售前景上調至 7500 萬至 8000 萬美元。錯過了反彈？瞭解下一批領導者將從何而來

Ionis posted Q2 EPS of 85 cents vs. a 52 cents loss expected, with revenue at $452 million, beating $282.95 million consensus. FY25 revenue guidance raised to $825-$850 million; Tryngolza sales outlook hiked to $75-$80 million. Missed the rally? Learn exactly where the next leaders are emerging ...

### Related Stocks

- [IONS.US - Ionis制藥](https://longbridge.com/zh-HK/quote/IONS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | In the latest quarter, 6 analysts provided mixed ratings for Ionis Pharmaceuticals (NASDAQ:IONS), with an average 12-mon | [Link](https://longbridge.com/zh-HK/news/275171994.md) |
| Ionis Pharmaceuticals: Underappreciated Bepirovirsen and Multiple Late-Stage Catalysts Support Buy Rating | William Blair analyst Myles Minter has reiterated a Buy rating on Ionis Pharmaceuticals (IONS) due to its promising late | [Link](https://longbridge.com/zh-HK/news/271790979.md) |
| Squarepoint Ops LLC Sells 170,978 Shares of Ionis Pharmaceuticals, Inc. $IONS | Squarepoint Ops LLC reduced its holdings in Ionis Pharmaceuticals by 56% in Q2, selling 170,978 shares. The firm now own | [Link](https://longbridge.com/zh-HK/news/269716130.md) |
| Barclays’ Supportive View on Ionis’s RNA Pipeline and Partnerships Might Change The Case For Investing In Ionis Pharmaceuticals (IONS) | Barclays analyst Eliana Merle has initiated coverage on Ionis Pharmaceuticals with a positive rating, highlighting its R | [Link](https://longbridge.com/zh-HK/news/274418851.md) |
| Ionis ramps up Angelman syndrome awareness with Lifetime segment | Ionis Pharmaceuticals is raising awareness for Angelman syndrome (AS) as it begins a phase 3 trial of its drug ION582. T | [Link](https://longbridge.com/zh-HK/news/270045716.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。